Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C13H13N3O |
| Molecular Weight | 227.2618 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=CC=C(C=C1)C(=O)NC2=C(N)C=CC=C2
InChI
InChIKey=QGMGHALXLXKCBD-UHFFFAOYSA-N
InChI=1S/C13H13N3O/c14-10-7-5-9(6-8-10)13(17)16-12-4-2-1-3-11(12)15/h1-8H,14-15H2,(H,16,17)
| Molecular Formula | C13H13N3O |
| Molecular Weight | 227.2618 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Dinaline represents a group of pharmacologically active lipophilic substances with a relatively simple structure derived from N-acyl-o-phenylenediamine. It has been found to exhibit high antineoplastic activity in a series of slowly growing tumors such as chemically induced rat mammary and colorectal carcinomas, osteosarcoma C22LR and Brown Norway myeloid leukemia. The drug was inactive against many of the typically hypersensitive signal tumors, i.e. mouse leukemias P388 and L1210, sarcoma 180 and Yoshida sarcoma. Colon carcinoma cells exposed to dinaline demonstrate distinct but reversible changes in amino acid transport, protein metabolism, DNA synthesis and cell proliferation.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006865 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8669814 |
|||
Target ID: GO:0051320 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8669814 |
|||
Target ID: GO:0071897 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8669814 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Application of alpha-aminoisobutyric acid, L-methionine, thymidine and 2-fluoro-2-deoxy-D-glucose to monitor effects of chemotherapy in a human colon carcinoma cell line. | 1996-01 |
|
| Dinaline inhibits amino acid transport and proliferation of colon carcinoma cells in vitro. | 1995-11-01 |
|
| Combination treatment based on metabolic effects of dinaline. | 1995 |
|
| Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia. | 1993-07-01 |
|
| On the long-term toxic risk of dinaline. | 1991-12-01 |
|
| New cytostatics--more activity and less toxicity. | 1990-09 |
|
| Dinaline: a new oral drug against leukemia? Preclinical studies in a relevant rat model for human acute myelocytic leukemia (BNML). | 1988-04 |
|
| Autochthonous, acetoxymethylmethylnitrosamine-induced colorectal cancer in rats: a useful tool in selecting new active antineoplastic compounds? | 1986-10 |
|
| Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2'-aminophenyl)-benzamide: a new compound preferentially active in slowly growing tumors. | 1985-12 |
|
| Effectiveness of P-aminobenzoyl-O-phenylenediamine (Goe 1734) against mouse, rat, and human tumour cells. | 1985 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8943683
Rat: 10, 7.7 and 5.9 mg/kg 5 days per week
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3859382
An in vitro clonogenic assay did not reveal any activity of Goe 1734 when mouse osteosarcoma or human tumour cells were exposed for only 1 h. However, continuous exposure led to 70% or greater inhibition of colony formation at concentrations of 0.1-1 ug/ml (osteosarcoma) or 0.2-2 ug/ml (human tumours).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:18:29 GMT 2025
by
admin
on
Mon Mar 31 18:18:29 GMT 2025
|
| Record UNII |
RG9G4Z82PY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1946
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C79870
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY | |||
|
DTXSID3046114
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY | |||
|
C045838
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY | |||
|
SUB07190MIG
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY | |||
|
42725
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY | |||
|
100000082670
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY | |||
|
5689
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY | |||
|
CHEMBL1351761
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY | |||
|
RG9G4Z82PY
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY | |||
|
328786
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY | |||
|
58338-59-3
Created by
admin on Mon Mar 31 18:18:29 GMT 2025 , Edited by admin on Mon Mar 31 18:18:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |